{"id":343831,"date":"2025-08-24T06:27:16","date_gmt":"2025-08-24T06:27:16","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-apellis-pharmaceuticals\/"},"modified":"2025-08-24T06:27:16","modified_gmt":"2025-08-24T06:27:16","slug":"how-to-buy-apellis-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","title":{"rendered":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-343831","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)","h1_source":{"label":"H1","type":"text","formatted_value":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)"},"description":"T\u00ecm hi\u1ec3u c\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals (APLS) v\u1edbi gi\u00e1 hi\u1ec7n t\u1ea1i $27,97. Kh\u00e1m ph\u00e1 c\u00e1c chi\u1ebfn l\u01b0\u1ee3c \u0111\u1ea7u t\u01b0, r\u1ee7i ro v\u00e0 ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng c\u1ee7a c\u00f4ng ty d\u1eabn \u0111\u1ea7u ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc n\u00e0y.","description_source":{"label":"Description","type":"textarea","formatted_value":"T\u00ecm hi\u1ec3u c\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals (APLS) v\u1edbi gi\u00e1 hi\u1ec7n t\u1ea1i $27,97. Kh\u00e1m ph\u00e1 c\u00e1c chi\u1ebfn l\u01b0\u1ee3c \u0111\u1ea7u t\u01b0, r\u1ee7i ro v\u00e0 ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng c\u1ee7a c\u00f4ng ty d\u1eabn \u0111\u1ea7u ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc n\u00e0y."},"intro":"B\u1ea1n \u0111ang ngh\u0129 \u0111\u1ebfn vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o m\u1ed9t c\u00f4ng ty \u0111ang c\u00e1ch m\u1ea1ng h\u00f3a \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh v\u1ec1 m\u1eaft? Apellis Pharmaceuticals \u0111\u1ea1i di\u1ec7n cho s\u1ef1 giao thoa th\u00fa v\u1ecb gi\u1eefa \u0111\u1ed5i m\u1edbi y h\u1ecdc v\u00e0 c\u01a1 h\u1ed9i \u0111\u1ea7u t\u01b0. V\u1edbi ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb \u0111\u1ed9t ph\u00e1 SYFOVRE cho b\u1ec7nh teo \u0111\u1ecba l\u00fd v\u00e0 c\u00e1c ph\u00ea duy\u1ec7t g\u1ea7n \u0111\u00e2y t\u1eeb FDA, c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc n\u00e0y mang l\u1ea1i c\u1ea3 ti\u1ec1m n\u0103ng khoa h\u1ecdc v\u00e0 t\u00e0i ch\u00ednh. H\u00e3y c\u00f9ng kh\u00e1m ph\u00e1 l\u00fd do t\u1ea1i sao c\u1ed5 phi\u1ebfu APLS x\u1ee9ng \u0111\u00e1ng \u0111\u01b0\u1ee3c b\u1ea1n quan t\u00e2m.","intro_source":{"label":"Intro","type":"text","formatted_value":"B\u1ea1n \u0111ang ngh\u0129 \u0111\u1ebfn vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o m\u1ed9t c\u00f4ng ty \u0111ang c\u00e1ch m\u1ea1ng h\u00f3a \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh v\u1ec1 m\u1eaft? Apellis Pharmaceuticals \u0111\u1ea1i di\u1ec7n cho s\u1ef1 giao thoa th\u00fa v\u1ecb gi\u1eefa \u0111\u1ed5i m\u1edbi y h\u1ecdc v\u00e0 c\u01a1 h\u1ed9i \u0111\u1ea7u t\u01b0. V\u1edbi ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb \u0111\u1ed9t ph\u00e1 SYFOVRE cho b\u1ec7nh teo \u0111\u1ecba l\u00fd v\u00e0 c\u00e1c ph\u00ea duy\u1ec7t g\u1ea7n \u0111\u00e2y t\u1eeb FDA, c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc n\u00e0y mang l\u1ea1i c\u1ea3 ti\u1ec1m n\u0103ng khoa h\u1ecdc v\u00e0 t\u00e0i ch\u00ednh. H\u00e3y c\u00f9ng kh\u00e1m ph\u00e1 l\u00fd do t\u1ea1i sao c\u1ed5 phi\u1ebfu APLS x\u1ee9ng \u0111\u00e1ng \u0111\u01b0\u1ee3c b\u1ea1n quan t\u00e2m."},"body_html":"<h2>V\u1ecb Tr\u00ed Th\u1ecb Tr\u01b0\u1eddng Hi\u1ec7n T\u1ea1i v\u00e0 \u0110i\u1ec3m V\u00e0o L\u1ec7nh<\/h2> <p>T\u00ednh \u0111\u1ebfn ng\u00e0y 24 th\u00e1ng 8 n\u0103m 2025, Apellis Pharmaceuticals (APLS) giao d\u1ecbch \u1edf m\u1ee9c <strong>27,97 USD<\/strong> m\u1ed7i c\u1ed5 phi\u1ebfu. M\u1ee9c gi\u00e1 n\u00e0y \u0111\u1ea1i di\u1ec7n cho m\u1ed9t b\u01b0\u1edbc ngo\u1eb7t quan tr\u1ecdng cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 \u0111ang c\u00e2n nh\u1eafc c\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS), khi c\u1ed5 phi\u1ebfu \u0111\u00e3 th\u1ec3 hi\u1ec7n \u0111\u00e0 ph\u1ee5c h\u1ed3i \u0111\u00e1ng k\u1ec3 trong nh\u1eefng th\u00e1ng g\u1ea7n \u0111\u00e2y.<\/p> <p><strong>C\u1ea3nh B\u00e1o Ng\u00e0y Quan Tr\u1ecdng<\/strong>: H\u00e3y \u0111\u00e1nh d\u1ea5u <strong>ng\u00e0y 4 th\u00e1ng 11 n\u0103m 2025<\/strong> v\u00e0o l\u1ecbch c\u1ee7a b\u1ea1n. \u0110\u00e2y l\u00e0 ng\u00e0y Apellis c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 3. C\u00e1c m\u1eabu h\u00ecnh l\u1ecbch s\u1eed cho th\u1ea5y c\u00e1c s\u1ef1 ki\u1ec7n n\u00e0y \u1ea3nh h\u01b0\u1edfng \u0111\u00e1ng k\u1ec3 \u0111\u1ebfn bi\u1ebfn \u0111\u1ed9ng gi\u00e1 c\u1ed5 phi\u1ebfu APLS.<\/p> <p><strong>Ph\u00e2n T\u00edch T\u00e1c \u0110\u1ed9ng Thu Nh\u1eadp<\/strong>:<br\/> Xem x\u00e9t c\u00e1c b\u00e1o c\u00e1o qu\u00fd g\u1ea7n \u0111\u00e2y, c\u1ed5 phi\u1ebfu Apellis th\u01b0\u1eddng tr\u1ea3i qua bi\u1ebfn \u0111\u1ed9ng gi\u00e1 t\u1eeb 5-15% quanh c\u00e1c th\u00f4ng b\u00e1o thu nh\u1eadp. B\u00e1o c\u00e1o qu\u00fd 2 n\u0103m 2025 v\u00e0o ng\u00e0y 31 th\u00e1ng 7 cho th\u1ea5y k\u1ebft qu\u1ea3 h\u1ed7n h\u1ee3p - doanh thu kh\u00f4ng \u0111\u1ea1t k\u1ef3 v\u1ecdng nh\u01b0ng l\u1ee3i nhu\u1eadn tr\u00ean m\u1ed7i c\u1ed5 phi\u1ebfu v\u01b0\u1ee3t \u01b0\u1edbc t\u00ednh 25%. M\u1eabu h\u00ecnh n\u00e0y cho th\u1ea5y vi\u1ec7c ph\u00e2n t\u00edch k\u1ef9 l\u01b0\u1ee1ng c\u1ea3 hi\u1ec7u qu\u1ea3 doanh thu v\u00e0 l\u1ee3i nhu\u1eadn l\u00e0 r\u1ea5t c\u1ea7n thi\u1ebft khi c\u00e2n nh\u1eafc \u0111\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS).<\/p> [cta_green text=\"B\u1eaft \u0111\u1ea7u giao d\u1ecbch\"]<h2>H\u00e0nh Tr\u00ecnh Gi\u00e1 S\u00e1u Th\u00e1ng: T\u1eeb Kh\u00f3 Kh\u0103n \u0110\u1ebfn M\u1ea1nh M\u1ebd<\/h2> <p>C\u1ed5 phi\u1ebfu Apellis \u0111\u00e3 tr\u1ea3i qua m\u1ed9t s\u1ef1 bi\u1ebfn \u0111\u1ed5i \u0111\u00e1ng k\u1ec3 trong s\u00e1u th\u00e1ng qua:<\/p> <ul> <li><strong>Th\u00e1ng 1 n\u0103m 2025<\/strong>: B\u1eaft \u0111\u1ea7u \u1edf kho\u1ea3ng 35,57 USD, sau \u0111\u00f3 b\u1eaft \u0111\u1ea7u gi\u1ea3m \u0111\u00e1ng lo ng\u1ea1i<\/li> <li><strong>Th\u00e1ng 2-3<\/strong>: \u00c1p l\u1ef1c gi\u1ea3m ti\u1ebfp t\u1ee5c, gi\u1ea3m xu\u1ed1ng v\u00f9ng 26-30 USD<\/li> <li><strong>Th\u00e1ng 4-5<\/strong>: \u0110\u1ea1t m\u1ee9c th\u1ea5p \u0111\u00e1ng lo ng\u1ea1i kho\u1ea3ng 16-17 USD, th\u1eed th\u00e1ch s\u1ef1 ki\u00ean nh\u1eabn c\u1ee7a nh\u00e0 \u0111\u1ea7u t\u01b0<\/li> <li><strong>Th\u00e1ng 6-7<\/strong>: Ph\u1ee5c h\u1ed3i \u1ea5n t\u01b0\u1ee3ng v\u1edbi m\u1ee9c t\u0103ng 2,24% v\u00e0 12,48% h\u00e0ng th\u00e1ng t\u01b0\u01a1ng \u1ee9ng<\/li> <li><strong>Th\u00e1ng 8 n\u0103m 2025<\/strong>: Ti\u1ebfp t\u1ee5c ph\u1ee5c h\u1ed3i, \u0111\u1ea1t m\u1ee9c hi\u1ec7n t\u1ea1i kho\u1ea3ng 28 USD<\/li> <\/ul> <p>\u0110\u00e2y l\u00e0 m\u1ed9t m\u1eabu bi\u1ebfn \u0111\u1ed9ng \u0111i\u1ec3n h\u00ecnh c\u1ee7a ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc - gi\u1ea3m m\u1ea1nh theo sau l\u00e0 ph\u1ee5c h\u1ed3i b\u00f9ng n\u1ed5. \u0110\u1ed1i v\u1edbi nh\u1eefng ng\u01b0\u1eddi \u0111ang h\u1ecdc c\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS), l\u1ecbch s\u1eed n\u00e0y cho th\u1ea5y c\u1ea3 r\u1ee7i ro v\u00e0 c\u01a1 h\u1ed9i trong \u0111\u1ea7u t\u01b0 d\u01b0\u1ee3c ph\u1ea9m.<\/p> <h2>D\u1ef1 B\u00e1o Gi\u00e1: Tri\u1ec3n V\u1ecdng 2025-2030<\/h2> <p>D\u1ef1a tr\u00ean s\u1ef1 \u0111\u1ed3ng thu\u1eadn c\u1ee7a c\u00e1c nh\u00e0 ph\u00e2n t\u00edch hi\u1ec7n t\u1ea1i v\u00e0 c\u00e1c ph\u00e1t tri\u1ec3n c\u1ee7a c\u00f4ng ty, \u0111\u00e2y l\u00e0 nh\u1eefng g\u00ec b\u1ea1n c\u00f3 th\u1ec3 mong \u0111\u1ee3i:<\/p> <ul> <li><strong>Cu\u1ed1i n\u0103m 2025<\/strong>: V\u00f9ng 30-34 USD (t\u0103ng tr\u01b0\u1edfng v\u1eeba ph\u1ea3i so v\u1edbi m\u1ee9c hi\u1ec7n t\u1ea1i)<\/li> <li><strong>D\u1ef1 b\u00e1o 2026<\/strong>: 28-32 USD (giai \u0111o\u1ea1n c\u1ee7ng c\u1ed1 d\u1ef1 ki\u1ebfn)<\/li> <li><strong>Tri\u1ec3n v\u1ecdng 2028<\/strong>: 48-52 USD (ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng \u0111\u00e1ng k\u1ec3 t\u1eeb vi\u1ec7c m\u1edf r\u1ed9ng danh m\u1ee5c s\u1ea3n ph\u1ea9m)<\/li> <li><strong>T\u1ea7m nh\u00ecn 2030<\/strong>: 50-55+ USD (t\u1ea1o gi\u00e1 tr\u1ecb d\u00e0i h\u1ea1n t\u1eeb v\u1ecb th\u1ebf d\u1eabn \u0111\u1ea7u th\u1ecb tr\u01b0\u1eddng)<\/li> <\/ul> <p><strong>K\u1ebft lu\u1eadn<\/strong>: <strong>MUA<\/strong> cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 d\u00e0i h\u1ea1n. Vi\u1ec7c FDA ph\u00ea duy\u1ec7t g\u1ea7n \u0111\u00e2y cho EMPAVELI v\u00e0 hi\u1ec7u su\u1ea5t m\u1ea1nh m\u1ebd c\u1ee7a SYFOVRE t\u1ea1o ra s\u1ee9c m\u1ea1nh n\u1ec1n t\u1ea3ng h\u1ed7 tr\u1ee3 t\u0103ng tr\u01b0\u1edfng trong t\u01b0\u01a1ng lai.<\/p> <h2>\u0110\u00e1nh Gi\u00e1 R\u1ee7i Ro so v\u1edbi C\u00e1c T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c<\/h2> <h3>\u26a0\ufe0f C\u00e1c R\u1ee7i Ro Ch\u00ednh C\u1ea7n Xem X\u00e9t:<\/h3> <ul> <li><strong>Kh\u00f4ng ch\u1eafc ch\u1eafn v\u1ec1 quy \u0111\u1ecbnh<\/strong>: C\u00e1c quy\u1ebft \u0111\u1ecbnh c\u1ee7a FDA c\u00f3 th\u1ec3 \u1ea3nh h\u01b0\u1edfng l\u1edbn \u0111\u1ebfn c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc<\/li> <li><strong>C\u1ea1nh tranh ng\u00e0y c\u00e0ng gay g\u1eaft<\/strong>: C\u00e1c c\u00f4ng ty kh\u00e1c \u0111ang ph\u00e1t tri\u1ec3n c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb t\u01b0\u01a1ng t\u1ef1<\/li> <li><strong>Lo ng\u1ea1i v\u1ec1 d\u00f2ng ti\u1ec1n<\/strong>: M\u1eb7c d\u00f9 c\u00f3 370 tri\u1ec7u USD ti\u1ec1n m\u1eb7t, chi ph\u00ed R&D v\u1eabn \u1edf m\u1ee9c cao<\/li> <li><strong>Bi\u1ebfn \u0111\u1ed9ng th\u1ecb tr\u01b0\u1eddng<\/strong>: C\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc th\u01b0\u1eddng c\u00f3 beta cao h\u01a1n m\u1ee9c trung b\u00ecnh th\u1ecb tr\u01b0\u1eddng<\/li> <\/ul> <h3>\u2705 T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c cho n\u0103m 2025:<\/h3> <ul> <li><strong>Th\u00e0nh c\u00f4ng ph\u00ea duy\u1ec7t FDA<\/strong>: EMPAVELI \u0111\u01b0\u1ee3c ph\u00ea duy\u1ec7t cho C3G\/IC-MPGN (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/07\/31\/3124861\/0\/en\/Apellis-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results.html\">B\u00e1o c\u00e1o Thu nh\u1eadp Qu\u00fd 2<\/a>)<\/li> <li><strong>T\u0103ng tr\u01b0\u1edfng doanh thu<\/strong>: SYFOVRE mang l\u1ea1i 151 tri\u1ec7u USD doanh thu qu\u00fd 2, t\u0103ng 6% theo qu\u00fd<\/li> <li><strong>\u0110\u1ed1i t\u00e1c chi\u1ebfn l\u01b0\u1ee3c<\/strong>: Th\u1ecfa thu\u1eadn b\u1ea3n quy\u1ec1n 300 tri\u1ec7u USD v\u1edbi Sobi cung c\u1ea5p s\u1ef1 \u1ed5n \u0111\u1ecbnh t\u00e0i ch\u00ednh<\/li> <li><strong>V\u1ecb th\u1ebf d\u1eabn \u0111\u1ea7u th\u1ecb tr\u01b0\u1eddng<\/strong>: SYFOVRE chi\u1ebfm h\u01a1n 60% th\u1ecb ph\u1ea7n b\u1ec7nh nh\u00e2n m\u1edbi trong b\u1ec7nh teo \u0111\u1ecba l\u00fd<\/li> <\/ul> <h2>Ph\u00e2n T\u00edch T\u00e1c \u0110\u1ed9ng Tin T\u1ee9c G\u1ea7n \u0110\u00e2y<\/h2> <p>Apellis \u0111\u00e3 t\u1ea1o ra nhi\u1ec1u d\u1ea5u \u1ea5n trong n\u0103m 2025 v\u1edbi m\u1ed9t s\u1ed1 ph\u00e1t tri\u1ec3n quan tr\u1ecdng:<\/p> <ul> <li><strong>Hi\u1ec7u su\u1ea5t Thu nh\u1eadp Qu\u00fd 2<\/strong>: M\u1eb7c d\u00f9 doanh thu 178 tri\u1ec7u USD kh\u00f4ng \u0111\u1ea1t k\u1ef3 v\u1ecdng, EPS v\u01b0\u1ee3t 25% cho th\u1ea5y hi\u1ec7u qu\u1ea3 v\u1eadn h\u00e0nh \u0111\u01b0\u1ee3c c\u1ea3i thi\u1ec7n (<a href=\"https:\/\/www.ainvest.com\/news\/apellis-pharmaceuticals-reports-q2-revenue-expectations-celebrates-fda-approval-empaveli-2508\/\">Ph\u00e2n t\u00edch AInvest<\/a>)<\/li> <li><strong>M\u1edf r\u1ed9ng FDA<\/strong>: Vi\u1ec7c ph\u00ea duy\u1ec7t EMPAVELI cho c\u00e1c \u0111i\u1ec1u ki\u1ec7n b\u1ed5 sung m\u1edf ra c\u01a1 h\u1ed9i th\u1ecb tr\u01b0\u1eddng ti\u1ec1m n\u0103ng 500 tri\u1ec7u USD m\u1ed7i b\u1ec7nh nh\u00e2n (<a href=\"https:\/\/www.ainvest.com\/news\/apellis-pharmaceuticals-q2-2025-unraveling-contradictions-sales-dynamics-market-position-competitive-landscape-2508\/\">Ph\u00e2n t\u00edch Th\u1ecb tr\u01b0\u1eddng<\/a>)<\/li> <li><strong>Ni\u1ec1m tin c\u1ee7a c\u00e1c t\u1ed5 ch\u1ee9c<\/strong>: \u0110\u1ea7u t\u01b0 m\u1edbi c\u1ee7a Fox Run Management v\u00e0o th\u00e1ng 8 n\u0103m 2025 b\u00e1o hi\u1ec7u s\u1ef1 quan t\u00e2m chuy\u00ean nghi\u1ec7p ti\u1ebfp t\u1ee5c (<a href=\"https:\/\/www.marketbeat.com\/instant-alerts\/filing-fox-run-management-llc-makes-new-investment-in-apellis-pharmaceuticals-inc-apls-2025-08-20\/\">H\u1ed3 s\u01a1 T\u1ed5 ch\u1ee9c<\/a>)<\/li> <\/ul> <h2>C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) T\u1eebng B\u01b0\u1edbc<\/h2> <table> <thead> <tr><th>B\u01b0\u1edbc<\/th><th>H\u00e0nh \u0110\u1ed9ng<\/th><th>T\u1ea1i Sao Quan Tr\u1ecdng<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Ch\u1ecdn n\u1ec1n t\u1ea3ng giao d\u1ecbch<\/td><td>\u0110\u1ea3m b\u1ea3o n\u1ec1n t\u1ea3ng cung c\u1ea5p truy c\u1eadp NASDAQ cho c\u1ed5 phi\u1ebfu M\u1ef9<\/td><\/tr> <tr><td>2<\/td><td>Ho\u00e0n t\u1ea5t x\u00e1c minh t\u00e0i kho\u1ea3n<\/td><td>H\u1ea7u h\u1ebft n\u1ec1n t\u1ea3ng y\u00eau c\u1ea7u x\u00e1c nh\u1eadn ID v\u00e0 \u0111\u1ecba ch\u1ec9<\/td><\/tr> <tr><td>3<\/td><td>N\u1ea1p ti\u1ec1n<\/td><td>B\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n b\u1ea1n c\u1ea3m th\u1ea5y tho\u1ea3i m\u00e1i khi r\u1ee7i ro<\/td><\/tr> <tr><td>4<\/td><td>Nghi\u00ean c\u1ee9u gi\u00e1 APLS hi\u1ec7n t\u1ea1i<\/td><td>Ki\u1ec3m tra b\u00e1o gi\u00e1 th\u1eddi gian th\u1ef1c tr\u01b0\u1edbc khi \u0111\u1eb7t l\u1ec7nh<\/td><\/tr> <tr><td>5<\/td><td>\u0110\u1eb7t l\u1ec7nh mua<\/td><td>S\u1eed d\u1ee5ng l\u1ec7nh gi\u1edbi h\u1ea1n \u0111\u1ec3 ki\u1ec3m so\u00e1t gi\u00e1 v\u00e0o l\u1ec7nh<\/td><\/tr> <tr><td>6<\/td><td>Gi\u00e1m s\u00e1t kho\u1ea3n \u0111\u1ea7u t\u01b0<\/td><td>\u0110\u1eb7t c\u1ea3nh b\u00e1o gi\u00e1 cho c\u00e1c m\u1ee9c quan tr\u1ecdng<\/td><\/tr> <tr><td>7<\/td><td>Xem x\u00e9t ph\u01b0\u01a1ng ph\u00e1p trung b\u00ecnh gi\u00e1 mua<\/td><td>Ph\u00e2n b\u1ed5 mua theo th\u1eddi gian \u0111\u1ec3 gi\u1ea3m r\u1ee7i ro v\u1ec1 th\u1eddi \u0111i\u1ec3m<\/td><\/tr> <\/tbody> <\/table> <h2>Chi\u1ebfn L\u01b0\u1ee3c Th\u00f4ng Minh Cho Ng\u01b0\u1eddi M\u1edbi<\/h2> <p>\u0110\u1ed1i v\u1edbi nh\u1eefng ng\u01b0\u1eddi m\u1edbi h\u1ecdc c\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS), \u0111\u00e2y l\u00e0 l\u1eddi khuy\u00ean chuy\u00ean nghi\u1ec7p c\u1ee7a t\u00f4i:<\/p> <ul> <li><strong>B\u1eaft \u0111\u1ea7u nh\u1ecf<\/strong> - C\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc c\u00f3 th\u1ec3 bi\u1ebfn \u0111\u1ed9ng; h\u00e3y b\u1eaft \u0111\u1ea7u v\u1edbi v\u1ecb th\u1ebf kh\u00f4ng l\u00e0m b\u1ea1n m\u1ea5t ng\u1ee7<\/li> <li><strong>T\u1eadp trung d\u00e0i h\u1ea1n<\/strong> - Ph\u00e1t tri\u1ec3n d\u01b0\u1ee3c ph\u1ea9m m\u1ea5t nhi\u1ec1u n\u0103m; h\u00e3y ngh\u0129 theo khung th\u1eddi gian 3-5 n\u0103m<\/li> <li><strong>\u0110a d\u1ea1ng h\u00f3a h\u1ee3p l\u00fd<\/strong> - \u0110\u1eebng \u0111\u1eb7t t\u1ea5t c\u1ea3 tr\u1ee9ng v\u00e0o m\u1ed9t gi\u1ecf c\u00f4ng ngh\u1ec7 sinh h\u1ecdc<\/li> <li><strong>\u0110\u1eb7t l\u1ec7nh d\u1eebng l\u1ed7<\/strong> - B\u1ea3o v\u1ec7 v\u1ed1n kh\u1ecfi c\u00e1c \u0111\u1ee3t gi\u1ea3m b\u1ea5t ng\u1edd<\/li> <\/ul> <p>V\u00e0 quan \u0111i\u1ec3m h\u00e0i h\u01b0\u1edbc c\u1ee7a t\u00f4i: \"Giao d\u1ecbch APLS gi\u1ed1ng nh\u01b0 xem nghi\u00ean c\u1ee9u y h\u1ecdc - \u0111\u00f4i khi b\u1ea1n c\u1ea7n d\u1ea1 d\u00e0y kh\u1ecfe \u0111\u1ec3 ch\u1ecbu \u0111\u1ef1ng c\u00e1c th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng, nh\u01b0ng c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb th\u00e0nh c\u00f4ng khi\u1ebfn m\u1ecdi ch\u1edd \u0111\u1ee3i \u0111\u1ec1u x\u1ee9ng \u0111\u00e1ng!\"<\/p> <h2>T\u1ea1i Sao Pocket Option Ph\u00f9 H\u1ee3p V\u1edbi Nh\u00e0 \u0110\u1ea7u T\u01b0 M\u1edbi<\/h2> <p>\u0110\u1ed1i v\u1edbi nh\u1eefng ai \u0111ang c\u00e2n nh\u1eafc c\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS), Pocket Option mang l\u1ea1i nhi\u1ec1u l\u1ee3i th\u1ebf:<\/p> <ul> <li><strong>S\u1ed1 ti\u1ec1n n\u1ea1p t\u1ed1i thi\u1ec3u ch\u1ec9 5 USD<\/strong> - Ho\u00e0n h\u1ea3o \u0111\u1ec3 th\u1eed nghi\u1ec7m chi\u1ebfn l\u01b0\u1ee3c v\u1edbi r\u1ee7i ro t\u1ed1i thi\u1ec3u<\/li> <li><strong>X\u00e1c minh nhanh ch\u00f3ng<\/strong> - B\u1eaft \u0111\u1ea7u giao d\u1ecbch nhanh ch\u00f3ng v\u1edbi vi\u1ec7c t\u1ea3i l\u00ean t\u00e0i li\u1ec7u \u0111\u01a1n gi\u1ea3n<\/li> <li><strong>Nhi\u1ec1u ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n<\/strong> - Truy c\u1eadp l\u1ee3i nhu\u1eadn qua nhi\u1ec1u ph\u01b0\u01a1ng th\u1ee9c ti\u1ec7n l\u1ee3i<\/li> <li><strong>N\u1ec1n t\u1ea3ng th\u00e2n thi\u1ec7n v\u1edbi ng\u01b0\u1eddi d\u00f9ng<\/strong> - Thi\u1ebft k\u1ebf cho ng\u01b0\u1eddi m\u1edbi b\u1eaft \u0111\u1ea7u \u0111\u1ed3ng th\u1eddi cung c\u1ea5p c\u00e1c t\u00ednh n\u0103ng n\u00e2ng cao<\/li> <\/ul> <h2>T\u1ed5ng Quan C\u00f4ng Ty: Apellis N\u0103m 2025<\/h2> <p>Apellis Pharmaceuticals l\u00e0 c\u00f4ng ty d\u1eabn \u0111\u1ea7u to\u00e0n c\u1ea7u trong \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh li\u00ean quan \u0111\u1ebfn h\u1ec7 th\u1ed1ng b\u1ed5 th\u1ec3. C\u00f4ng ty \u0111\u00e3 chuy\u1ec3n t\u1eeb giai \u0111o\u1ea1n th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng sang giai \u0111o\u1ea1n th\u01b0\u01a1ng m\u1ea1i th\u00e0nh c\u00f4ng v\u1edbi hai li\u1ec7u ph\u00e1p \u0111\u01b0\u1ee3c ph\u00ea duy\u1ec7t nh\u1eb1m \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh nghi\u00eam tr\u1ecdng.<\/p> <p>S\u1ea3n ph\u1ea9m ch\u1ee7 l\u1ef1c SYFOVRE \u0111i\u1ec1u tr\u1ecb b\u1ec7nh teo \u0111\u1ecba l\u00fd, trong khi EMPAVELI x\u1eed l\u00fd nhi\u1ec1u b\u1ec7nh hi\u1ebfm kh\u00e1c nhau. V\u1edbi 370 tri\u1ec7u USD ti\u1ec1n m\u1eb7t v\u00e0 d\u00f2ng doanh thu ng\u00e0y c\u00e0ng t\u0103ng, Apellis th\u1ec3 hi\u1ec7n c\u1ea3 s\u1ef1 \u0111\u1ed5i m\u1edbi khoa h\u1ecdc v\u00e0 n\u0103ng l\u1ef1c kinh doanh.<\/p> <p><strong>S\u1ef1 Th\u1eadt Th\u00fa V\u1ecb<\/strong>: N\u0103m 2025, Apellis \u0111\u00e3 \u0111\u1ea1t \u0111\u01b0\u1ee3c \u0111i\u1ec1u hi\u1ebfm th\u1ea5y trong ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc - h\u1ecd \u0111\u00e3 m\u1edf r\u1ed9ng th\u00e0nh c\u00f4ng thu\u1ed1c EMPAVELI hi\u1ec7n c\u00f3 \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh ho\u00e0n to\u00e0n m\u1edbi (C3G v\u00e0 IC-MPGN), t\u1ea1o ra c\u00e1c d\u00f2ng doanh thu m\u1edbi m\u00e0 kh\u00f4ng c\u1ea7n ph\u00e1t tri\u1ec3n ho\u00e0n to\u00e0n c\u00e1c h\u1ee3p ch\u1ea5t m\u1edbi t\u1eeb \u0111\u1ea7u!<\/p> <p>\u0110\u1ec3 c\u00f3 th\u00eam n\u1ed9i dung gi\u00e1o d\u1ee5c v\u1ec1 chi\u1ebfn l\u01b0\u1ee3c giao d\u1ecbch v\u00e0 ph\u00e2n t\u00edch th\u1ecb tr\u01b0\u1eddng, h\u00e3y truy c\u1eadp <a href=\"\/blog\">blog Pocket Option<\/a> c\u1ee7a ch\u00fang t\u00f4i \u0111\u1ec3 c\u1eadp nh\u1eadt v\u00e0 nh\u1eadn \u0111\u1ecbnh th\u01b0\u1eddng xuy\u00ean.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>V\u1ecb Tr\u00ed Th\u1ecb Tr\u01b0\u1eddng Hi\u1ec7n T\u1ea1i v\u00e0 \u0110i\u1ec3m V\u00e0o L\u1ec7nh<\/h2>\n<p>T\u00ednh \u0111\u1ebfn ng\u00e0y 24 th\u00e1ng 8 n\u0103m 2025, Apellis Pharmaceuticals (APLS) giao d\u1ecbch \u1edf m\u1ee9c <strong>27,97 USD<\/strong> m\u1ed7i c\u1ed5 phi\u1ebfu. M\u1ee9c gi\u00e1 n\u00e0y \u0111\u1ea1i di\u1ec7n cho m\u1ed9t b\u01b0\u1edbc ngo\u1eb7t quan tr\u1ecdng cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 \u0111ang c\u00e2n nh\u1eafc c\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS), khi c\u1ed5 phi\u1ebfu \u0111\u00e3 th\u1ec3 hi\u1ec7n \u0111\u00e0 ph\u1ee5c h\u1ed3i \u0111\u00e1ng k\u1ec3 trong nh\u1eefng th\u00e1ng g\u1ea7n \u0111\u00e2y.<\/p>\n<p><strong>C\u1ea3nh B\u00e1o Ng\u00e0y Quan Tr\u1ecdng<\/strong>: H\u00e3y \u0111\u00e1nh d\u1ea5u <strong>ng\u00e0y 4 th\u00e1ng 11 n\u0103m 2025<\/strong> v\u00e0o l\u1ecbch c\u1ee7a b\u1ea1n. \u0110\u00e2y l\u00e0 ng\u00e0y Apellis c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 3. C\u00e1c m\u1eabu h\u00ecnh l\u1ecbch s\u1eed cho th\u1ea5y c\u00e1c s\u1ef1 ki\u1ec7n n\u00e0y \u1ea3nh h\u01b0\u1edfng \u0111\u00e1ng k\u1ec3 \u0111\u1ebfn bi\u1ebfn \u0111\u1ed9ng gi\u00e1 c\u1ed5 phi\u1ebfu APLS.<\/p>\n<p><strong>Ph\u00e2n T\u00edch T\u00e1c \u0110\u1ed9ng Thu Nh\u1eadp<\/strong>:<br \/> Xem x\u00e9t c\u00e1c b\u00e1o c\u00e1o qu\u00fd g\u1ea7n \u0111\u00e2y, c\u1ed5 phi\u1ebfu Apellis th\u01b0\u1eddng tr\u1ea3i qua bi\u1ebfn \u0111\u1ed9ng gi\u00e1 t\u1eeb 5-15% quanh c\u00e1c th\u00f4ng b\u00e1o thu nh\u1eadp. B\u00e1o c\u00e1o qu\u00fd 2 n\u0103m 2025 v\u00e0o ng\u00e0y 31 th\u00e1ng 7 cho th\u1ea5y k\u1ebft qu\u1ea3 h\u1ed7n h\u1ee3p &#8211; doanh thu kh\u00f4ng \u0111\u1ea1t k\u1ef3 v\u1ecdng nh\u01b0ng l\u1ee3i nhu\u1eadn tr\u00ean m\u1ed7i c\u1ed5 phi\u1ebfu v\u01b0\u1ee3t \u01b0\u1edbc t\u00ednh 25%. M\u1eabu h\u00ecnh n\u00e0y cho th\u1ea5y vi\u1ec7c ph\u00e2n t\u00edch k\u1ef9 l\u01b0\u1ee1ng c\u1ea3 hi\u1ec7u qu\u1ea3 doanh thu v\u00e0 l\u1ee3i nhu\u1eadn l\u00e0 r\u1ea5t c\u1ea7n thi\u1ebft khi c\u00e2n nh\u1eafc \u0111\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS).<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/vt\/register\/\" class=\"po-cta-green\">B\u1eaft \u0111\u1ea7u giao d\u1ecbch\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>H\u00e0nh Tr\u00ecnh Gi\u00e1 S\u00e1u Th\u00e1ng: T\u1eeb Kh\u00f3 Kh\u0103n \u0110\u1ebfn M\u1ea1nh M\u1ebd<\/h2>\n<p>C\u1ed5 phi\u1ebfu Apellis \u0111\u00e3 tr\u1ea3i qua m\u1ed9t s\u1ef1 bi\u1ebfn \u0111\u1ed5i \u0111\u00e1ng k\u1ec3 trong s\u00e1u th\u00e1ng qua:<\/p>\n<ul>\n<li><strong>Th\u00e1ng 1 n\u0103m 2025<\/strong>: B\u1eaft \u0111\u1ea7u \u1edf kho\u1ea3ng 35,57 USD, sau \u0111\u00f3 b\u1eaft \u0111\u1ea7u gi\u1ea3m \u0111\u00e1ng lo ng\u1ea1i<\/li>\n<li><strong>Th\u00e1ng 2-3<\/strong>: \u00c1p l\u1ef1c gi\u1ea3m ti\u1ebfp t\u1ee5c, gi\u1ea3m xu\u1ed1ng v\u00f9ng 26-30 USD<\/li>\n<li><strong>Th\u00e1ng 4-5<\/strong>: \u0110\u1ea1t m\u1ee9c th\u1ea5p \u0111\u00e1ng lo ng\u1ea1i kho\u1ea3ng 16-17 USD, th\u1eed th\u00e1ch s\u1ef1 ki\u00ean nh\u1eabn c\u1ee7a nh\u00e0 \u0111\u1ea7u t\u01b0<\/li>\n<li><strong>Th\u00e1ng 6-7<\/strong>: Ph\u1ee5c h\u1ed3i \u1ea5n t\u01b0\u1ee3ng v\u1edbi m\u1ee9c t\u0103ng 2,24% v\u00e0 12,48% h\u00e0ng th\u00e1ng t\u01b0\u01a1ng \u1ee9ng<\/li>\n<li><strong>Th\u00e1ng 8 n\u0103m 2025<\/strong>: Ti\u1ebfp t\u1ee5c ph\u1ee5c h\u1ed3i, \u0111\u1ea1t m\u1ee9c hi\u1ec7n t\u1ea1i kho\u1ea3ng 28 USD<\/li>\n<\/ul>\n<p>\u0110\u00e2y l\u00e0 m\u1ed9t m\u1eabu bi\u1ebfn \u0111\u1ed9ng \u0111i\u1ec3n h\u00ecnh c\u1ee7a ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc &#8211; gi\u1ea3m m\u1ea1nh theo sau l\u00e0 ph\u1ee5c h\u1ed3i b\u00f9ng n\u1ed5. \u0110\u1ed1i v\u1edbi nh\u1eefng ng\u01b0\u1eddi \u0111ang h\u1ecdc c\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS), l\u1ecbch s\u1eed n\u00e0y cho th\u1ea5y c\u1ea3 r\u1ee7i ro v\u00e0 c\u01a1 h\u1ed9i trong \u0111\u1ea7u t\u01b0 d\u01b0\u1ee3c ph\u1ea9m.<\/p>\n<h2>D\u1ef1 B\u00e1o Gi\u00e1: Tri\u1ec3n V\u1ecdng 2025-2030<\/h2>\n<p>D\u1ef1a tr\u00ean s\u1ef1 \u0111\u1ed3ng thu\u1eadn c\u1ee7a c\u00e1c nh\u00e0 ph\u00e2n t\u00edch hi\u1ec7n t\u1ea1i v\u00e0 c\u00e1c ph\u00e1t tri\u1ec3n c\u1ee7a c\u00f4ng ty, \u0111\u00e2y l\u00e0 nh\u1eefng g\u00ec b\u1ea1n c\u00f3 th\u1ec3 mong \u0111\u1ee3i:<\/p>\n<ul>\n<li><strong>Cu\u1ed1i n\u0103m 2025<\/strong>: V\u00f9ng 30-34 USD (t\u0103ng tr\u01b0\u1edfng v\u1eeba ph\u1ea3i so v\u1edbi m\u1ee9c hi\u1ec7n t\u1ea1i)<\/li>\n<li><strong>D\u1ef1 b\u00e1o 2026<\/strong>: 28-32 USD (giai \u0111o\u1ea1n c\u1ee7ng c\u1ed1 d\u1ef1 ki\u1ebfn)<\/li>\n<li><strong>Tri\u1ec3n v\u1ecdng 2028<\/strong>: 48-52 USD (ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng \u0111\u00e1ng k\u1ec3 t\u1eeb vi\u1ec7c m\u1edf r\u1ed9ng danh m\u1ee5c s\u1ea3n ph\u1ea9m)<\/li>\n<li><strong>T\u1ea7m nh\u00ecn 2030<\/strong>: 50-55+ USD (t\u1ea1o gi\u00e1 tr\u1ecb d\u00e0i h\u1ea1n t\u1eeb v\u1ecb th\u1ebf d\u1eabn \u0111\u1ea7u th\u1ecb tr\u01b0\u1eddng)<\/li>\n<\/ul>\n<p><strong>K\u1ebft lu\u1eadn<\/strong>: <strong>MUA<\/strong> cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 d\u00e0i h\u1ea1n. Vi\u1ec7c FDA ph\u00ea duy\u1ec7t g\u1ea7n \u0111\u00e2y cho EMPAVELI v\u00e0 hi\u1ec7u su\u1ea5t m\u1ea1nh m\u1ebd c\u1ee7a SYFOVRE t\u1ea1o ra s\u1ee9c m\u1ea1nh n\u1ec1n t\u1ea3ng h\u1ed7 tr\u1ee3 t\u0103ng tr\u01b0\u1edfng trong t\u01b0\u01a1ng lai.<\/p>\n<h2>\u0110\u00e1nh Gi\u00e1 R\u1ee7i Ro so v\u1edbi C\u00e1c T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c<\/h2>\n<h3>\u26a0\ufe0f C\u00e1c R\u1ee7i Ro Ch\u00ednh C\u1ea7n Xem X\u00e9t:<\/h3>\n<ul>\n<li><strong>Kh\u00f4ng ch\u1eafc ch\u1eafn v\u1ec1 quy \u0111\u1ecbnh<\/strong>: C\u00e1c quy\u1ebft \u0111\u1ecbnh c\u1ee7a FDA c\u00f3 th\u1ec3 \u1ea3nh h\u01b0\u1edfng l\u1edbn \u0111\u1ebfn c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc<\/li>\n<li><strong>C\u1ea1nh tranh ng\u00e0y c\u00e0ng gay g\u1eaft<\/strong>: C\u00e1c c\u00f4ng ty kh\u00e1c \u0111ang ph\u00e1t tri\u1ec3n c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb t\u01b0\u01a1ng t\u1ef1<\/li>\n<li><strong>Lo ng\u1ea1i v\u1ec1 d\u00f2ng ti\u1ec1n<\/strong>: M\u1eb7c d\u00f9 c\u00f3 370 tri\u1ec7u USD ti\u1ec1n m\u1eb7t, chi ph\u00ed R&#038;D v\u1eabn \u1edf m\u1ee9c cao<\/li>\n<li><strong>Bi\u1ebfn \u0111\u1ed9ng th\u1ecb tr\u01b0\u1eddng<\/strong>: C\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc th\u01b0\u1eddng c\u00f3 beta cao h\u01a1n m\u1ee9c trung b\u00ecnh th\u1ecb tr\u01b0\u1eddng<\/li>\n<\/ul>\n<h3>\u2705 T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c cho n\u0103m 2025:<\/h3>\n<ul>\n<li><strong>Th\u00e0nh c\u00f4ng ph\u00ea duy\u1ec7t FDA<\/strong>: EMPAVELI \u0111\u01b0\u1ee3c ph\u00ea duy\u1ec7t cho C3G\/IC-MPGN (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/07\/31\/3124861\/0\/en\/Apellis-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results.html\">B\u00e1o c\u00e1o Thu nh\u1eadp Qu\u00fd 2<\/a>)<\/li>\n<li><strong>T\u0103ng tr\u01b0\u1edfng doanh thu<\/strong>: SYFOVRE mang l\u1ea1i 151 tri\u1ec7u USD doanh thu qu\u00fd 2, t\u0103ng 6% theo qu\u00fd<\/li>\n<li><strong>\u0110\u1ed1i t\u00e1c chi\u1ebfn l\u01b0\u1ee3c<\/strong>: Th\u1ecfa thu\u1eadn b\u1ea3n quy\u1ec1n 300 tri\u1ec7u USD v\u1edbi Sobi cung c\u1ea5p s\u1ef1 \u1ed5n \u0111\u1ecbnh t\u00e0i ch\u00ednh<\/li>\n<li><strong>V\u1ecb th\u1ebf d\u1eabn \u0111\u1ea7u th\u1ecb tr\u01b0\u1eddng<\/strong>: SYFOVRE chi\u1ebfm h\u01a1n 60% th\u1ecb ph\u1ea7n b\u1ec7nh nh\u00e2n m\u1edbi trong b\u1ec7nh teo \u0111\u1ecba l\u00fd<\/li>\n<\/ul>\n<h2>Ph\u00e2n T\u00edch T\u00e1c \u0110\u1ed9ng Tin T\u1ee9c G\u1ea7n \u0110\u00e2y<\/h2>\n<p>Apellis \u0111\u00e3 t\u1ea1o ra nhi\u1ec1u d\u1ea5u \u1ea5n trong n\u0103m 2025 v\u1edbi m\u1ed9t s\u1ed1 ph\u00e1t tri\u1ec3n quan tr\u1ecdng:<\/p>\n<ul>\n<li><strong>Hi\u1ec7u su\u1ea5t Thu nh\u1eadp Qu\u00fd 2<\/strong>: M\u1eb7c d\u00f9 doanh thu 178 tri\u1ec7u USD kh\u00f4ng \u0111\u1ea1t k\u1ef3 v\u1ecdng, EPS v\u01b0\u1ee3t 25% cho th\u1ea5y hi\u1ec7u qu\u1ea3 v\u1eadn h\u00e0nh \u0111\u01b0\u1ee3c c\u1ea3i thi\u1ec7n (<a href=\"https:\/\/www.ainvest.com\/news\/apellis-pharmaceuticals-reports-q2-revenue-expectations-celebrates-fda-approval-empaveli-2508\/\">Ph\u00e2n t\u00edch AInvest<\/a>)<\/li>\n<li><strong>M\u1edf r\u1ed9ng FDA<\/strong>: Vi\u1ec7c ph\u00ea duy\u1ec7t EMPAVELI cho c\u00e1c \u0111i\u1ec1u ki\u1ec7n b\u1ed5 sung m\u1edf ra c\u01a1 h\u1ed9i th\u1ecb tr\u01b0\u1eddng ti\u1ec1m n\u0103ng 500 tri\u1ec7u USD m\u1ed7i b\u1ec7nh nh\u00e2n (<a href=\"https:\/\/www.ainvest.com\/news\/apellis-pharmaceuticals-q2-2025-unraveling-contradictions-sales-dynamics-market-position-competitive-landscape-2508\/\">Ph\u00e2n t\u00edch Th\u1ecb tr\u01b0\u1eddng<\/a>)<\/li>\n<li><strong>Ni\u1ec1m tin c\u1ee7a c\u00e1c t\u1ed5 ch\u1ee9c<\/strong>: \u0110\u1ea7u t\u01b0 m\u1edbi c\u1ee7a Fox Run Management v\u00e0o th\u00e1ng 8 n\u0103m 2025 b\u00e1o hi\u1ec7u s\u1ef1 quan t\u00e2m chuy\u00ean nghi\u1ec7p ti\u1ebfp t\u1ee5c (<a href=\"https:\/\/www.marketbeat.com\/instant-alerts\/filing-fox-run-management-llc-makes-new-investment-in-apellis-pharmaceuticals-inc-apls-2025-08-20\/\">H\u1ed3 s\u01a1 T\u1ed5 ch\u1ee9c<\/a>)<\/li>\n<\/ul>\n<h2>C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) T\u1eebng B\u01b0\u1edbc<\/h2>\n<table>\n<thead>\n<tr>\n<th>B\u01b0\u1edbc<\/th>\n<th>H\u00e0nh \u0110\u1ed9ng<\/th>\n<th>T\u1ea1i Sao Quan Tr\u1ecdng<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Ch\u1ecdn n\u1ec1n t\u1ea3ng giao d\u1ecbch<\/td>\n<td>\u0110\u1ea3m b\u1ea3o n\u1ec1n t\u1ea3ng cung c\u1ea5p truy c\u1eadp NASDAQ cho c\u1ed5 phi\u1ebfu M\u1ef9<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Ho\u00e0n t\u1ea5t x\u00e1c minh t\u00e0i kho\u1ea3n<\/td>\n<td>H\u1ea7u h\u1ebft n\u1ec1n t\u1ea3ng y\u00eau c\u1ea7u x\u00e1c nh\u1eadn ID v\u00e0 \u0111\u1ecba ch\u1ec9<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>N\u1ea1p ti\u1ec1n<\/td>\n<td>B\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n b\u1ea1n c\u1ea3m th\u1ea5y tho\u1ea3i m\u00e1i khi r\u1ee7i ro<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Nghi\u00ean c\u1ee9u gi\u00e1 APLS hi\u1ec7n t\u1ea1i<\/td>\n<td>Ki\u1ec3m tra b\u00e1o gi\u00e1 th\u1eddi gian th\u1ef1c tr\u01b0\u1edbc khi \u0111\u1eb7t l\u1ec7nh<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0110\u1eb7t l\u1ec7nh mua<\/td>\n<td>S\u1eed d\u1ee5ng l\u1ec7nh gi\u1edbi h\u1ea1n \u0111\u1ec3 ki\u1ec3m so\u00e1t gi\u00e1 v\u00e0o l\u1ec7nh<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Gi\u00e1m s\u00e1t kho\u1ea3n \u0111\u1ea7u t\u01b0<\/td>\n<td>\u0110\u1eb7t c\u1ea3nh b\u00e1o gi\u00e1 cho c\u00e1c m\u1ee9c quan tr\u1ecdng<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Xem x\u00e9t ph\u01b0\u01a1ng ph\u00e1p trung b\u00ecnh gi\u00e1 mua<\/td>\n<td>Ph\u00e2n b\u1ed5 mua theo th\u1eddi gian \u0111\u1ec3 gi\u1ea3m r\u1ee7i ro v\u1ec1 th\u1eddi \u0111i\u1ec3m<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Chi\u1ebfn L\u01b0\u1ee3c Th\u00f4ng Minh Cho Ng\u01b0\u1eddi M\u1edbi<\/h2>\n<p>\u0110\u1ed1i v\u1edbi nh\u1eefng ng\u01b0\u1eddi m\u1edbi h\u1ecdc c\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS), \u0111\u00e2y l\u00e0 l\u1eddi khuy\u00ean chuy\u00ean nghi\u1ec7p c\u1ee7a t\u00f4i:<\/p>\n<ul>\n<li><strong>B\u1eaft \u0111\u1ea7u nh\u1ecf<\/strong> &#8211; C\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc c\u00f3 th\u1ec3 bi\u1ebfn \u0111\u1ed9ng; h\u00e3y b\u1eaft \u0111\u1ea7u v\u1edbi v\u1ecb th\u1ebf kh\u00f4ng l\u00e0m b\u1ea1n m\u1ea5t ng\u1ee7<\/li>\n<li><strong>T\u1eadp trung d\u00e0i h\u1ea1n<\/strong> &#8211; Ph\u00e1t tri\u1ec3n d\u01b0\u1ee3c ph\u1ea9m m\u1ea5t nhi\u1ec1u n\u0103m; h\u00e3y ngh\u0129 theo khung th\u1eddi gian 3-5 n\u0103m<\/li>\n<li><strong>\u0110a d\u1ea1ng h\u00f3a h\u1ee3p l\u00fd<\/strong> &#8211; \u0110\u1eebng \u0111\u1eb7t t\u1ea5t c\u1ea3 tr\u1ee9ng v\u00e0o m\u1ed9t gi\u1ecf c\u00f4ng ngh\u1ec7 sinh h\u1ecdc<\/li>\n<li><strong>\u0110\u1eb7t l\u1ec7nh d\u1eebng l\u1ed7<\/strong> &#8211; B\u1ea3o v\u1ec7 v\u1ed1n kh\u1ecfi c\u00e1c \u0111\u1ee3t gi\u1ea3m b\u1ea5t ng\u1edd<\/li>\n<\/ul>\n<p>V\u00e0 quan \u0111i\u1ec3m h\u00e0i h\u01b0\u1edbc c\u1ee7a t\u00f4i: &#8220;Giao d\u1ecbch APLS gi\u1ed1ng nh\u01b0 xem nghi\u00ean c\u1ee9u y h\u1ecdc &#8211; \u0111\u00f4i khi b\u1ea1n c\u1ea7n d\u1ea1 d\u00e0y kh\u1ecfe \u0111\u1ec3 ch\u1ecbu \u0111\u1ef1ng c\u00e1c th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng, nh\u01b0ng c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb th\u00e0nh c\u00f4ng khi\u1ebfn m\u1ecdi ch\u1edd \u0111\u1ee3i \u0111\u1ec1u x\u1ee9ng \u0111\u00e1ng!&#8221;<\/p>\n<h2>T\u1ea1i Sao Pocket Option Ph\u00f9 H\u1ee3p V\u1edbi Nh\u00e0 \u0110\u1ea7u T\u01b0 M\u1edbi<\/h2>\n<p>\u0110\u1ed1i v\u1edbi nh\u1eefng ai \u0111ang c\u00e2n nh\u1eafc c\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS), Pocket Option mang l\u1ea1i nhi\u1ec1u l\u1ee3i th\u1ebf:<\/p>\n<ul>\n<li><strong>S\u1ed1 ti\u1ec1n n\u1ea1p t\u1ed1i thi\u1ec3u ch\u1ec9 5 USD<\/strong> &#8211; Ho\u00e0n h\u1ea3o \u0111\u1ec3 th\u1eed nghi\u1ec7m chi\u1ebfn l\u01b0\u1ee3c v\u1edbi r\u1ee7i ro t\u1ed1i thi\u1ec3u<\/li>\n<li><strong>X\u00e1c minh nhanh ch\u00f3ng<\/strong> &#8211; B\u1eaft \u0111\u1ea7u giao d\u1ecbch nhanh ch\u00f3ng v\u1edbi vi\u1ec7c t\u1ea3i l\u00ean t\u00e0i li\u1ec7u \u0111\u01a1n gi\u1ea3n<\/li>\n<li><strong>Nhi\u1ec1u ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n<\/strong> &#8211; Truy c\u1eadp l\u1ee3i nhu\u1eadn qua nhi\u1ec1u ph\u01b0\u01a1ng th\u1ee9c ti\u1ec7n l\u1ee3i<\/li>\n<li><strong>N\u1ec1n t\u1ea3ng th\u00e2n thi\u1ec7n v\u1edbi ng\u01b0\u1eddi d\u00f9ng<\/strong> &#8211; Thi\u1ebft k\u1ebf cho ng\u01b0\u1eddi m\u1edbi b\u1eaft \u0111\u1ea7u \u0111\u1ed3ng th\u1eddi cung c\u1ea5p c\u00e1c t\u00ednh n\u0103ng n\u00e2ng cao<\/li>\n<\/ul>\n<h2>T\u1ed5ng Quan C\u00f4ng Ty: Apellis N\u0103m 2025<\/h2>\n<p>Apellis Pharmaceuticals l\u00e0 c\u00f4ng ty d\u1eabn \u0111\u1ea7u to\u00e0n c\u1ea7u trong \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh li\u00ean quan \u0111\u1ebfn h\u1ec7 th\u1ed1ng b\u1ed5 th\u1ec3. C\u00f4ng ty \u0111\u00e3 chuy\u1ec3n t\u1eeb giai \u0111o\u1ea1n th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng sang giai \u0111o\u1ea1n th\u01b0\u01a1ng m\u1ea1i th\u00e0nh c\u00f4ng v\u1edbi hai li\u1ec7u ph\u00e1p \u0111\u01b0\u1ee3c ph\u00ea duy\u1ec7t nh\u1eb1m \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh nghi\u00eam tr\u1ecdng.<\/p>\n<p>S\u1ea3n ph\u1ea9m ch\u1ee7 l\u1ef1c SYFOVRE \u0111i\u1ec1u tr\u1ecb b\u1ec7nh teo \u0111\u1ecba l\u00fd, trong khi EMPAVELI x\u1eed l\u00fd nhi\u1ec1u b\u1ec7nh hi\u1ebfm kh\u00e1c nhau. V\u1edbi 370 tri\u1ec7u USD ti\u1ec1n m\u1eb7t v\u00e0 d\u00f2ng doanh thu ng\u00e0y c\u00e0ng t\u0103ng, Apellis th\u1ec3 hi\u1ec7n c\u1ea3 s\u1ef1 \u0111\u1ed5i m\u1edbi khoa h\u1ecdc v\u00e0 n\u0103ng l\u1ef1c kinh doanh.<\/p>\n<p><strong>S\u1ef1 Th\u1eadt Th\u00fa V\u1ecb<\/strong>: N\u0103m 2025, Apellis \u0111\u00e3 \u0111\u1ea1t \u0111\u01b0\u1ee3c \u0111i\u1ec1u hi\u1ebfm th\u1ea5y trong ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc &#8211; h\u1ecd \u0111\u00e3 m\u1edf r\u1ed9ng th\u00e0nh c\u00f4ng thu\u1ed1c EMPAVELI hi\u1ec7n c\u00f3 \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh ho\u00e0n to\u00e0n m\u1edbi (C3G v\u00e0 IC-MPGN), t\u1ea1o ra c\u00e1c d\u00f2ng doanh thu m\u1edbi m\u00e0 kh\u00f4ng c\u1ea7n ph\u00e1t tri\u1ec3n ho\u00e0n to\u00e0n c\u00e1c h\u1ee3p ch\u1ea5t m\u1edbi t\u1eeb \u0111\u1ea7u!<\/p>\n<p>\u0110\u1ec3 c\u00f3 th\u00eam n\u1ed9i dung gi\u00e1o d\u1ee5c v\u1ec1 chi\u1ebfn l\u01b0\u1ee3c giao d\u1ecbch v\u00e0 ph\u00e2n t\u00edch th\u1ecb tr\u01b0\u1eddng, h\u00e3y truy c\u1eadp <a href=\"\/blog\">blog Pocket Option<\/a> c\u1ee7a ch\u00fang t\u00f4i \u0111\u1ec3 c\u1eadp nh\u1eadt v\u00e0 nh\u1eadn \u0111\u1ecbnh th\u01b0\u1eddng xuy\u00ean.<\/p>\n"},"faq":[{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)?","answer":"B\u1ea1n c\u1ea7n ch\u1ecdn m\u1ed9t n\u1ec1n t\u1ea3ng giao d\u1ecbch c\u00f3 truy c\u1eadp NASDAQ, ho\u00e0n t\u1ea5t x\u00e1c minh t\u00e0i kho\u1ea3n, n\u1ea1p ti\u1ec1n, ki\u1ec3m tra gi\u00e1 c\u1ed5 phi\u1ebfu hi\u1ec7n t\u1ea1i, \u0111\u1eb7t l\u1ec7nh mua v\u00e0 theo d\u00f5i \u0111\u1ea7u t\u01b0 c\u1ee7a m\u00ecnh."},{"question":"C\u1ed5 phi\u1ebfu APLS c\u00f3 ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng nh\u01b0 th\u1ebf n\u00e0o trong t\u01b0\u01a1ng lai?","answer":"D\u1ef1 b\u00e1o gi\u00e1 cho n\u0103m 2025 \u0111\u1ebfn 2030 cho th\u1ea5y c\u1ed5 phi\u1ebfu c\u00f3 th\u1ec3 t\u0103ng t\u1eeb 30-34 USD v\u00e0o cu\u1ed1i n\u0103m 2025 l\u00ean \u0111\u1ebfn 50-55+ USD v\u00e0o n\u0103m 2030 nh\u1edd s\u1ef1 m\u1edf r\u1ed9ng danh m\u1ee5c s\u1ea3n ph\u1ea9m v\u00e0 v\u1ecb th\u1ebf th\u1ecb tr\u01b0\u1eddng."},{"question":"Nh\u1eefng r\u1ee7i ro ch\u00ednh khi \u0111\u1ea7u t\u01b0 v\u00e0o Apellis Pharmaceuticals l\u00e0 g\u00ec?","answer":"C\u00e1c r\u1ee7i ro bao g\u1ed3m kh\u00f4ng ch\u1eafc ch\u1eafn v\u1ec1 quy \u0111\u1ecbnh FDA, c\u1ea1nh tranh gia t\u0103ng, chi ph\u00ed nghi\u00ean c\u1ee9u v\u00e0 ph\u00e1t tri\u1ec3n cao, v\u00e0 bi\u1ebfn \u0111\u1ed9ng th\u1ecb tr\u01b0\u1eddng c\u00f4ng ngh\u1ec7 sinh h\u1ecdc."},{"question":"T\u1ea1i sao n\u00ean s\u1eed d\u1ee5ng Pocket Option \u0111\u1ec3 mua c\u1ed5 phi\u1ebfu APLS?","answer":"Pocket Option c\u00f3 s\u1ed1 ti\u1ec1n n\u1ea1p t\u1ed1i thi\u1ec3u th\u1ea5p, x\u00e1c minh nhanh, nhi\u1ec1u ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n v\u00e0 n\u1ec1n t\u1ea3ng th\u00e2n thi\u1ec7n v\u1edbi ng\u01b0\u1eddi d\u00f9ng, ph\u00f9 h\u1ee3p cho nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi."},{"question":"Apellis Pharmaceuticals c\u00f3 nh\u1eefng s\u1ea3n ph\u1ea9m ch\u00ednh n\u00e0o?","answer":"Apellis c\u00f3 hai s\u1ea3n ph\u1ea9m ch\u00ednh l\u00e0 SYFOVRE \u0111i\u1ec1u tr\u1ecb teo \u0111\u1ecba l\u00fd v\u00e0 EMPAVELI \u0111i\u1ec1u tr\u1ecb nhi\u1ec1u b\u1ec7nh hi\u1ebfm, v\u1edbi c\u00e1c ph\u00ea duy\u1ec7t FDA g\u1ea7n \u0111\u00e2y gi\u00fap m\u1edf r\u1ed9ng th\u1ecb tr\u01b0\u1eddng."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)?","answer":"B\u1ea1n c\u1ea7n ch\u1ecdn m\u1ed9t n\u1ec1n t\u1ea3ng giao d\u1ecbch c\u00f3 truy c\u1eadp NASDAQ, ho\u00e0n t\u1ea5t x\u00e1c minh t\u00e0i kho\u1ea3n, n\u1ea1p ti\u1ec1n, ki\u1ec3m tra gi\u00e1 c\u1ed5 phi\u1ebfu hi\u1ec7n t\u1ea1i, \u0111\u1eb7t l\u1ec7nh mua v\u00e0 theo d\u00f5i \u0111\u1ea7u t\u01b0 c\u1ee7a m\u00ecnh."},{"question":"C\u1ed5 phi\u1ebfu APLS c\u00f3 ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng nh\u01b0 th\u1ebf n\u00e0o trong t\u01b0\u01a1ng lai?","answer":"D\u1ef1 b\u00e1o gi\u00e1 cho n\u0103m 2025 \u0111\u1ebfn 2030 cho th\u1ea5y c\u1ed5 phi\u1ebfu c\u00f3 th\u1ec3 t\u0103ng t\u1eeb 30-34 USD v\u00e0o cu\u1ed1i n\u0103m 2025 l\u00ean \u0111\u1ebfn 50-55+ USD v\u00e0o n\u0103m 2030 nh\u1edd s\u1ef1 m\u1edf r\u1ed9ng danh m\u1ee5c s\u1ea3n ph\u1ea9m v\u00e0 v\u1ecb th\u1ebf th\u1ecb tr\u01b0\u1eddng."},{"question":"Nh\u1eefng r\u1ee7i ro ch\u00ednh khi \u0111\u1ea7u t\u01b0 v\u00e0o Apellis Pharmaceuticals l\u00e0 g\u00ec?","answer":"C\u00e1c r\u1ee7i ro bao g\u1ed3m kh\u00f4ng ch\u1eafc ch\u1eafn v\u1ec1 quy \u0111\u1ecbnh FDA, c\u1ea1nh tranh gia t\u0103ng, chi ph\u00ed nghi\u00ean c\u1ee9u v\u00e0 ph\u00e1t tri\u1ec3n cao, v\u00e0 bi\u1ebfn \u0111\u1ed9ng th\u1ecb tr\u01b0\u1eddng c\u00f4ng ngh\u1ec7 sinh h\u1ecdc."},{"question":"T\u1ea1i sao n\u00ean s\u1eed d\u1ee5ng Pocket Option \u0111\u1ec3 mua c\u1ed5 phi\u1ebfu APLS?","answer":"Pocket Option c\u00f3 s\u1ed1 ti\u1ec1n n\u1ea1p t\u1ed1i thi\u1ec3u th\u1ea5p, x\u00e1c minh nhanh, nhi\u1ec1u ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n v\u00e0 n\u1ec1n t\u1ea3ng th\u00e2n thi\u1ec7n v\u1edbi ng\u01b0\u1eddi d\u00f9ng, ph\u00f9 h\u1ee3p cho nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi."},{"question":"Apellis Pharmaceuticals c\u00f3 nh\u1eefng s\u1ea3n ph\u1ea9m ch\u00ednh n\u00e0o?","answer":"Apellis c\u00f3 hai s\u1ea3n ph\u1ea9m ch\u00ednh l\u00e0 SYFOVRE \u0111i\u1ec1u tr\u1ecb teo \u0111\u1ecba l\u00fd v\u00e0 EMPAVELI \u0111i\u1ec1u tr\u1ecb nhi\u1ec1u b\u1ec7nh hi\u1ebfm, v\u1edbi c\u00e1c ph\u00ea duy\u1ec7t FDA g\u1ea7n \u0111\u00e2y gi\u00fap m\u1edf r\u1ed9ng th\u1ecb tr\u01b0\u1eddng."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>C\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-24T06:27:16+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)\",\"datePublished\":\"2025-08-24T06:27:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\"},\"wordCount\":23,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\",\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"datePublished\":\"2025-08-24T06:27:16+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/vt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vt-VT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-24T06:27:16+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)","datePublished":"2025-08-24T06:27:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"},"wordCount":23,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"vt-VT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","datePublished":"2025-08-24T06:27:16+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#breadcrumb"},"inLanguage":"vt-VT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/vt\/"},{"@type":"ListItem","position":2,"name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/vt\/#website","url":"https:\/\/pocketoption.com\/blog\/vt\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vt-VT"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"vt_VT","wpml_translations":{"pt_AA":{"locale":"pt_AA","id":343827,"slug":"how-to-buy-apellis-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da Apellis Pharmaceuticals, Inc. (APLS) - Investimento em a\u00e7\u00f5es da Apellis Pharmaceuticals, Inc. (APLS)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/343831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/comments?post=343831"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/343831\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media\/334081"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media?parent=343831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/categories?post=343831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/tags?post=343831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}